Induction Therapy with Basiliximab versus Thymoglobulin in African-American Kidney Transplant Recipients

2005 ◽  
Vol 79 (6) ◽  
pp. 716-721 ◽  
Author(s):  
Abdolreza Haririan ◽  
Katherina Morawski ◽  
Dale H. Sillix ◽  
Jose M. El-Amm ◽  
James Garnick ◽  
...  
2009 ◽  
Vol 23 (5) ◽  
pp. 500-505 ◽  
Author(s):  
James N. Fleming ◽  
David J. Taber ◽  
Nicole A. Weimert ◽  
Maria F. Egidi ◽  
John McGillicuddy ◽  
...  

2017 ◽  
Vol 266 (3) ◽  
pp. 450-456 ◽  
Author(s):  
David J. Taber ◽  
John W. McGillicuddy ◽  
Charles F. Bratton ◽  
Vinayak S. Rohan ◽  
Satish Nadig ◽  
...  

2016 ◽  
Vol 21 (1) ◽  
pp. e12823 ◽  
Author(s):  
Cole N. Crowson ◽  
Rhiannon D. Reed ◽  
Brittany A. Shelton ◽  
Paul A. MacLennan ◽  
Jayme E. Locke

2020 ◽  
Vol 26 (28) ◽  
pp. 3451-3459
Author(s):  
Tomáš Seeman

: Kidney transplantation is a preferable treatment of children with end-stage kidney disease. All kidney transplant recipients, including pediatric need immunosuppressive medications to prevent rejection episodes and graft loss. : Induction therapy is used temporarily only immediately following transplantation while maintenance immunosuppressive drugs are started and given long-term. There is currently no consensus regarding the use of induction therapy in children; its use should be decided based on the immunological risk of the child. : The recent progress shows that the recommended strategy is to use as maintenance immunosuppressive therapy a combination of a calcineurin inhibitor (preferably tacrolimus) with an antiproliferative drug (preferably mycophenolate mofetil) with steroids that can be withdrawn early or late in low-risk children. The mTOR-inhibitors (sirolimus, everolimus) are used rarely in pediatrics because of common side effects and no evidence of a benefit over calcineurin inhibitors. The use of calcineurin inhibitors, mycophenolate, and mTOR-inhibitors should be followed by therapeutic drug monitoring. : Immunosuppressive therapy of acute rejection consists of high-dose steroids and/or anti-lymphocyte antibodies (T-cell mediated rejection) or plasma exchange, intravenous immunoglobulines and/or rituximab (antibodymediated rejection). : The future strategies for research are mainly precise characterisation of children needing induction therapy, more specific indications for mTOR-inhibitors and for the far future, the possibility to reach the immuno tolerance.


2019 ◽  
pp. e13442 ◽  
Author(s):  
Kalathil K. Sureshkumar ◽  
Vinaikumar Katragadda ◽  
Bhavna Chopra ◽  
Marcelo Sampaio

2016 ◽  
Vol 30 (2) ◽  
pp. 82
Author(s):  
Yaerim Kim ◽  
Seong Sik Kang ◽  
Woo Yeong Park ◽  
Kyubok Jin ◽  
Sung Bae Park ◽  
...  

2020 ◽  
Vol 35 (Supplement_3) ◽  
Author(s):  
Yeonsoon Jung ◽  
Jisu Kim ◽  
Haesu Jeon ◽  
Ye Na Kim ◽  
Ho Sik Shin ◽  
...  

Abstract Background African American kidney transplant recipients experience disproportionately high rates of graft loss. The aim of this analysis was to use a UNOS data set that contains detailed baseline and longitudinal clinical data to establish and quantify the impact of the current overall graft loss definition on suppressing the true disparity magnitude in US AA kidney transplant outcomes. Methods Longitudinal cohort study of kidney transplant recipients using a data set created by United Network for Organ Sharing (UNOS), including 266,128 (African American 70,215, Non-African American 195,913) transplant patient between 1987 and December 2016. Multivariable analysis was conducted using 2-stage joint modeling of random and fixed effects of longitudinal data (linear mixed model) with time to event outcomes (Cox regression). Results 195,913 non-African American (AA) (73.6%) were compared with 70,215 AA (26.4%) recipients. 10-year-graft survival of AA in all era is lower than that of non-AA (31% in deceased kidney transplants (DKT) AA recipient and 42% in living kidney transplantation (LKT) non-AA recipient). 10-year-patient survival of AA with functioning graft in all era is similar that of non-AA. Multivariate Cox regression of factors associated with patient survival with functioning graft are acute rejection within 6 months, DM, hypertension and etc. Pre-transplant recipient BMI in AA show the trend as a protective factor in patient survival with functioning graft although not significantly in statistics Conclusions African American kidney transplant recipients experience a substantial disparity in graft loss, but not patient death with functioning graft.


Sign in / Sign up

Export Citation Format

Share Document